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Abstract 
The current trend on diabetes management advocates replacing the paradigm from a uniform 
to an individualized patient-centered systolic blood pressure, but there is no consensus on the 
achieved treatment goals of systolic blood pressure level. The study aimed at evaluating the 
association between systolic blood pressure and the risk of cardiovascular diseases and 
all-cause mortality for diabetic patients to identify patient-centered treatment targets. A 
retrospective study was conducted on 95,086 Chinese adult primary care patients with type 2 
diabetes mellitus and hypertension. Using the average of the annual systolic blood pressure 
records(‘updated systolic blood pressure’) over a median follow-up of 5.9 years, the risks of 
overall cardiovascular diseases, all-cause mortality and their composite associated with 
systolic blood pressure were evaluated using Cox proportional hazards regression. Subgroup 
analysis was performed on the incidence of cardiovascular diseases by stratifying patient’s 
baseline characteristics. The systolic blood pressure range for the lowest risk of 
cardiovascular diseases and all-cause mortality was 130-134mmHg among type 2 diabetes 
mellitus population. A J-shaped curvilinear relationship was identified between systolic blood 
pressure and risk of cardiovascular diseases and all-cause mortality, irrespective of patients’ 
characteristics. The findings showed that all patients with systolic blood pressure<125mmHg 
or ≥140mmHg had an increased risk of cardiovascular diseases and mortality. This large 
territory wide study showed the level of achieved systolic blood pressure of 125-139mmHg 
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in pharmacological therapy, irrespective of patients’ characteristics, suggested the systolic 
blood pressure treatment goal of <140mmHg and individualized systolic blood pressure 
target may not be necessary in diabetic management. 
 
Keywords: Systolic blood pressure; Cardiovascular diseases; Type 2 diabetes mellitus; 
Hypertension; Mortality, Primary care 
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Manuscript Text 
 
Introduction 
The risks of cardiovascular diseases (CVD) and all-cause mortality in patients with Diabetes 
Mellitus (DM) are thought to be related to suboptimal blood pressure (BP) control over a 
period of time, but the achieved target for pharmacologic BP lowering remains unclear. As 
one of the key goals of diabetes management is to minimize the risk of events 1-7, knowledge 
of the optimum achieved BP range in preventing CVD and all-cause mortality is important to 
help inform clinical practice and policy planning. 
 
Many international guidelines provide a systolic blood pressure (SBP) target as one of the 
goals for diabetic management. However, there is currently no consensus on the optimal 
SBP target varying from 130mmHg to 140mmHg 1-7. The discrepancy results across several 
randomized controlled trials (RCTs) showed that the benefits of intensive SBP control on 
CVD or mortality was still a matter of prolonged controversy 8-10. Inconsistent associations 
between SBP and risk of CVD and mortality have been found in several epidemiological 
studies, with some suggesting a positive linear, J-shaped or U-shaped relationship 11-16. Due 
to the heterogeneity of diabetic populations, a few studies also advocated that the aggressive 
treatment may not be appropriate for all patients and a rigid and uniform target should be 
replaced to a more flexible and patient-centered target for diabetic patients 4. These 
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conflicting evidences leave clinicians with a high level of uncertainty to the optimal SBP 
target. Furthermore, the global trend is towards shifting delivery of diabetic care away from 
hospitals to primary care 17, and most of results from previous studies under RCTs or 
hospital-based settings may not be fully transferable to diabetic patient managed in 
real-world primary care setting. Understanding the relationship between SBP and the 
incidences of CVD and all-cause mortality among hypertensive and diabetic patients with 
different characteristics in primary care, the risk reduction that can be achieved through 
controlling SBP and the achieved treatment goals of SBP level in pharmacological therapy 
can assist clinicians in setting evidence-based SBP targets and recommendations for 
intervention. 
 
The aim of this study was to investigate the association between SBP with the incidence of 
CVD events and all-cause mortality in treated patients with hypertension and Type 2 DM 
(T2DM), and explore the variation of the relationship among different characteristics such as 
gender, age, smoking status, duration of DM, body mass index (BMI), kidney function, 
severity of comorbidities and treatment modalities. 
 
Methods 
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Study Design 
This was a territory-wide retrospective cohort study that included all Chinese patients aged 
18 or above, who were clinically diagnosed with T2DM and hypertension and without prior 
history of CVD before baseline and received DM management in primary care. Clinical data 
were collected from the administrative database of the Hong Kong Hospital Authority (HA) 
for patients who had received primary care services from any of the 74 general out-patient 
clinics of the HA between 1 January 2009 and 31 December 2010. The HA is the governing 
body of all public-sector hospitals and primary care clinics in Hong Kong. Due to large 
subsidized public health care system managing in Hong Kong, the HA provides care for at 
least 90% of the diagnosed local diabetic patients 18. The date of the first prescription of 
anti-hypertensive drugs between 1 January 2009 and 31 December 2010 was defined as 
baseline. Each patient was followed-up until the date of diagnosis of an outcome event, death 
or last follow-up as of the censoring date of 30 November 2015, whichever occurred first. 
 
Clinical diagnosis of T2DM and hypertension were identified using the International 
Classification of Primary Care-2 (ICPC-2) code of ‘T90’ and ‘K86’/’K87’, respectively. The 
primary outcomes of interest was incidence of composite of all-cause mortality and CVD, 
including coronary heart disease (CHD), stroke and heart failure. The secondary outcomes 
were CVD, each subtype of CVD and all-cause mortality. CHD including ischaemic heart 
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disease, myocardial infarction, coronary death and sudden death was identified by ICPC-2 of 
K74 to K76 or International Classification of Diseases, Ninth Edition, Clinical Modification 
(ICD-9-CM) of 410.x, 411.x to 414.x, 798.x. Heart failure was identified by ICPC-2 of K77 
or ICD-9-CM of 428.x. Stroke including fatal and non-fatal was identified by ICPC-2 of 
K89 to K91 or ICD-9-CM of 430.x to 438.x. Although there was no validation study 
performed to assess the accuracy and completeness of the coding, a previous study showed 
that only 1.5% and 5.5% of records were miscoded or lacked coding, respectively, for the 
diagnosis of DM using ICPC-2 in the clinical management system of HA 19. Moreover, in 
routine clinical practice, clinicians in clinical and hospital settings provide ICPC-2 and 
ICD-9-CM codes, respectively, for each episode of attendance 20, 21. Another study also 
demonstrated reliability of the administrative database of HA to capture demographics and 
use of anti-diabetic drugs with an almost perfect level of data completeness regarding 
demographics (100%) and drug prescription (99.98%) 20. Furthermore, due to heavily 
subsidized health care system in Hong Kong, patients with chronic diseases and serious 
complication, e.g. myocardial infarction, were mostly treated in the HA public health care 
system. Therefore, the cohort in the present study should have captured nearly all CVD 
outcomes of DM patients who are managed in the HA primary care setting. In term of 
mortality data, the records were extracted from the Hong Kong Death Registry, which is a 
population-based government official registry covering all registered deaths for the residents 
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of Hong Kong. These mortality data have been used widely in governmental departments; 
and thus should be highly reliable. 
 
Consent of participants was not necessary as all data were anonymous and were extracted 
through the computerized administrative system of the Hospital Authority. Ethics approval 
was received from all the regional Institutional Review Boards (IRB) of the Hong Kong 
Hospital Authority. This study complies with the Declaration of Helsinki AND Title 45, U.S. 
Code of Federal Regulations, Part 46, Protection of Human Subjects, Revised November 13, 
2001, effective December 13, 2001. 
 
Updated BP and Measurements 
The guideline for obtaining and documenting SBP readings in diabetic patients during 
baseline and follow-up were standardized amongst all general outpatient clinics 22. SBP was 
measured multiple times at each single visit, with an interval of at least 1 minute, after at least 
5 minutes without any distractions in seated position, using a standardized semi-automated 
oscillometric devices (UA-853, Tokyo, Japan; or EDAN M3A, Shenzhen, China). If the 
difference between the two readings exceeded 5mmHg, an additional measurement was 
performed. The record of each SBP measurement was defined as the average of these 
readings.  
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The ‘updated’ SBP value was defined as the average of all annual SBP measurements. For 
instance, if the follow-up period was 2 years, then the updated mean value was calculated by 
averaging the baseline, one-year and two-year SBP measurements. This approach has been 
widely used to investigate the association between clinical parameter and the incidences of 
morbidity and mortality 12, 23, 24. The average number of SBP readings recorded was 6.0, and 
at least 93.0% had at least three SBP records until last follow-up among our subjects. 
 
Baseline covariates consisted of patient’s socio-demographics, clinical parameters, disease 
characteristics and treatment modalities. Socio-demographics included gender, age and 
smoking status. Clinical parameters included hemoglobin A1c (HbA1c), BMI, diastolic blood 
pressure (DBP), lipid profile (low-density lipoprotein-cholesterol (LDL-C) and total 
cholesterol to high-density lipoprotein-cholesterol ratio (TC/HDL-C ratio)), triglyceride (TG) 
and estimated glomerular filtration rate (eGFR). Disease characteristics included 
self-reported duration of diabetes mellitus. Co-morbidity was measured using the Charlson’s 
comorbidity index 25, 26. Treatment modalities composed of the usages of anti-hypertensive 
drug (e.g. angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
(ACEI/ARB), β-blocker, calcium channel blocker (CCB), diuretics and others (hydralazine, 
methyldopa and prazosin)), oral anti-diabetic drugs, insulin and lipid-lowering agents. All 
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laboratory assays were performed in accredited laboratories by the College of American 
Pathologists, the Hong Kong Accreditation Service or the National Association of Testing 
Authorities, Australia. 
 
Data Analysis 
Multiple imputation was used to handle missing data for baseline covariates (except SBP) 27. 
In this study, each missing value was imputed five times by the chained equation method. For 
each of the five imputed datasets, the same analysis was performed with the five sets of 
results combined based on Rubin’s rules 28. All subjects were categorized as one of ten 
groups according to the updated SBP value (< 120mmHg, 120-124mmHg, 125-129mmHg, 
130-134mmHg, 135-139mmHg, 140-144mmHg, 145-149mmHg, 150-154mmHg, 
155-159mmHg and ≥ 160mmHg). Descriptive statistics were shown after multiple imputation 
for each subgroup of SBP. The incidence rate was estimated by an exact 95% confidence 
interval (CI) based on a Poisson distribution 29. The SBP groups associated with the incidence 
of CVD were examined using multivariable Cox proportional hazards regressions, adjusted 
by all baseline covariates. Moreover, the nonlinear association between updated SBP and 
CVD for each outcomes were assessed by the restricted cubic splines with three knots in Cox 
models 30. The proportional hazards assumption was checked by examining plots of the 
scaled Schoenfeld residuals against time for the covariates. Presence of multi-collinearity was 
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also checked by examining the variance inflation factor. Analysis of the data showed that all 
models fulfilled proportional hazards assumption and no multi-collinearity existed. To 
eliminate the potential bias from the imbalance number of patients in current groups, the 
main analyses were repeated by dividing the cohort into decile group of updated SBP levels. 
Four scenarios on the exclusion of patients either with follow-up period less than or equal to 
1 year after baseline or with history of lung disease, cancer or chronic kidney disease on or 
before baseline, and with complete data were subsequently performed as sensitivity analyses 
to avoid potential bias due to severe disease at baseline.  
 
Subgroup analysis was performed on the incidence of composite of CVD and all-cause 
mortality by stratifying gender, age groups (< 50 years, 50-64 years, 65-79 years, ≥ 80 years), 
duration of DM (< 2 years, ≥ 2 years), smoking status (non-smoker, smoker), BMI groups (< 
23kg/m2; 23kg/m2-24.9kg/m2; BMI ≥ 25kg/m2), SBP (≤ 129mmHg;:129-141mmHg; 
141-153mmHg; ≥ 153mmHg), eGFR (< 60ml/min/1.73m2, ≥ 60ml/min/1.73m2), Charlson’s 
Index (< 5, ≥ 5), number of types of anti-hypertensive drugs used (1 kind, 2 kinds, ≥ 3 kinds) 
and usages of ACEI/ARB, β-blocker, CCB and diuretic at baseline.  
 
All significance tests were two-tailed and those with a p-value less than 0.05 were considered 
statistically significant. The statistical analysis was performed in Stata Version 13.0. 
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Results 
There were a total of 106,101 Chinese patients with T2DM aged 18 or above with valid SBP 
measurements and received DM care in one of the primary care clinics of HA between 1 
January 2009 and 31 December 2010. A total of 95,086 diabetic patients were included in the 
data analysis after excluding 10,981 patients with CVD history and 34 patients without 
follow-up after baseline. Data completion rates for most baseline factors were greater than 
85%. 
 
The baseline characteristics for overall cohort and each SBP group after multiple imputation 
are summarized in Table 1. As a whole, 42.8% were male; mean age was 66.7 years 
(Standard Deviation (SD): 11.0 years); Updated SBP was 137.6mmHg (SD: 10.7mmHg). The 
number and unadjusted incidence rates of the four outcome events for each SBP group are 
shown in Table 2. During a median follow-up period of 51.5-81.5 months, the incidence 
rates of CVD were between 19.5 and 105.5 per 1,000 person-years among SBP groups. 
Multivariable Cox proportional hazards regressions were also performed and the 
corresponding hazard ratios for the marginal effects of SBP are shown and plotted in Figure 
1 and Figure S1 with and without restricted cubic spline. After adjusting for all baseline 
characteristics, the J-shaped associations between SBP level and incidence for each outcome 
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were preserved. In terms of SBP, group 4 (130-134mmHg), the reference group, had the 
lowest risk of CVD and mortality and patients with SBP <125mmHg or ≥140mmHg had 
significantly higher risk. Repeated analysis by dividing the cohort into decile group of 
updated SBP levels in Tables S2, S3 and Figure S2 demonstrated similar J-shaped 
association between SBP level and the outcomes. Four different sensitivity analyses were 
performed by considering exclusion of 1) patients with follow-up period less than or equal to 
1 year after baseline; 2) patients with history of lung disease, cancer or chronic kidney 
disease on or before baseline; 3) both (1) and (2), and; 4) with complete data. The results 
obtained were almost identical to the main analysis of a J-shaped curvilinear relationship 
between SBP level and CVD incidence with an optimal SBP range between 130-134mmHg 
for each outcome. Similar J-shaped pattern (Figure S3) was observed on the risk of CVD by 
stratifying gender, age group, duration of DM, smoking status, SBP, BMI, eGFR, Charlson’s 
index and usages of different anti-hypertensive drugs at baseline.  
 
Discussion 
This population-based cohort study is the first to examine the effect of SBP on the risks of 
CVD and all-cause mortality amongst Chinese hypertensive patients with T2DM managed 
in primary care. A key finding from this study identified the optimal level of achieved SBP 
of 125-139mmHg for the lowest risk of having all-cause mortality and CVD event including 
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CHD, stroke and heart failure, which supports the SBP target of 140mmHg in several 
international guidance in diabetic management. The current findings also demonstrated a 
J-shaped curvilinear relationship between SBP and incidence of CVD and all-cause 
mortality among diabetic population, irrespective of patients’ characteristics, and thus lower 
BP is not always better and may even be potentially hazardous. While the J-curve pattern 
was shifted slightly to the right in patients with age ≥ 65 years, similar results were obtained 
that patients with SBP < 125mmHg or ≥ 140mmHg had an increased risk of CVD and 
mortality. Hence, the individualized SBP target may not be necessary in diabetic 
management. 
 
Our findings were consistent with the results of previous clinical trials and observational 
studies which have also found a J-shape relationship between BP and cardiovascular 
outcomes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD), Cochrane 
review and two meta-analyses also concluded that lower BP targets (SBP < 120mmHg for 
ACCORD; SBP < 130mmHg for other) do not reduce macrovascular complications and 
mortality, but can increase the risk of adverse events attributed to hypertensive therapy 8-10, 31. 
While ACCORD illustrated the advantage of the treatment SBP goal below 120mmHg on 
stroke in RCT 31, a post-hoc analysis from ACCORD showed that achieving SBP 
<120mmHg cannot attenuate the risk of all-cause mortality, overall CVD, myocardial 
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infarction and stroke compared to achieving SBP 120-140mmHg 32, 33. A cohort study 
conducted in the US found similar results with the current study that SBP < 110mmHg was 
associated with increased risks of CHD, stroke and heart failure 11-13. Two observational 
studies conducted in the UK also found an increased incidence of mortality at SBP < 
125mmHg 15, 16. A meta-analysis also demonstrated that antihypertensive treatment 
evaluated the risk of mortality caused by CVD at SBP < 140mmHg 34. There is still no 
consensus on why low BP levels are associated with higher risks of CVD and all-cause 
mortality 35, 36. Possible reason may be attributable to underperfusion, some unmeasured 
variables such as frailty and undiagnosed heart failure 15, 37.  
 
Conversely, the United Kingdom Prospective Diabetes Study (UKPDS) identified a positive 
linear relationship between SBP and macrovascular complications and mortality, concluding 
that diabetic patients with SBP < 120mmHg had the lowest risk of events 14. The Systolic 
Blood Pressure Intervention Trial (SPRINT) also reached the same conclusion with UKPDS 
among patients at high risk for CVD but without diabetes 38. In comparing this current 
study’s findings to earlier studies, our study had a much larger sample size of subjects with 
SBP < 120mmHg and is better powered to examine the outcomes of patients with lower SBP. 
On the other hand, the unattended automated office BP measurements, which aims to 
minimise the white coat effect, was used in SPRINT 38, and thus the BP values in SPRINT 
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may underestimate conventional office BP measurements by ranging from 5mmHg to 
16mmHg 39. Several concern groups pointed out that caution should be taken when 
translating the SPRINT targets into the real world clinical practices 40-42 as same targets 
applied in routine practices may fall into the left side of the J-curve. 
 
Of interest, the findings from the present study showed the J-curve pattern was shifted 
slightly to the right in older patients but patients with SBP ≥140mmHg had an increased risk 
of CVD and mortality, irrespective of patients’ age. A few updated international guidelines 
advocated a looser treatment SBP for elderly patients 1, 5. For example, the Eighth Joint 
National Committee (JNC 8) Report and the International Diabetes Federation advocated 
treatment goal for SBP of < 150mmHg for patients aged ≥ 60 and ≥ 80 years, respectively 1, 
5. Nevertheless, two landmark randomized controlled trials, SHEP (Systolic Hypertension in 
Elderly Program) for persons aged ≥ 60 years and HYVET (Hypertension in the Very 
Elderly Trial) for persons aged ≥ 80 years, showed the benefit of treating hypertension for 
SBP to around 140 mmHg on health outcomes including mortality, stroke and heart failure 
43, 44. A recent prospective cohort study conducted in the general population aged 65 to 94 
years from Australia also provided evidence that there was a direct positive association 
between SBP and CVD throughout the SBP ranging from 145 to 170mmHg, even at 85-94 
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years 45. Our results indicated that this increased risk for CVD event and mortality extends 
to patients with SBP >140 mmHg regardless their age. 
 
This study consisted of a large number of diabetic patients, and thus a greater number of 
events allowed a more precise estimate on the strength of association. A multiple repeated 
measurement for SBP, regression and stratified analyses were able to evaluate the 
association between SBP and outcome events comprehensively. Clinical characteristics were 
closely captured by the HA’s computerised administrative database allowing accurate access 
to relevant baseline covariates such as laboratory results, disease characteristics and 
treatment modalities. Multiple imputations were used to replace the missing data to avoid 
biased results. 
 
There were also several limitations to this study. Firstly, our design was a retrospective 
cohort study which evaluates associations but not causation. To confirm the association 
between BP and CVD and all-cause mortality among Chinese diabetic patients, a more 
convincing study design like RCT would be required. Nonetheless, the common limitations 
of RCTs like UKPDS included high attrition rates, low number of incident events, short 
follow-up times and strict subject’s inclusion criteria that reduce the applicability to diabetic 
patients in clinical practices, with building evidence to supported the value of observational 
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studies in producing similar results to RCTs 46-48. In addition, the probability of reverse 
causation was low in the current study as all our patients were without previous CVD at 
baseline, and the results were very similar in sensitivity analysis after excluding patients with 
follow-up period less than or equal to 1 year or with history of lung disease, cancer or 
chronic kidney disease. The current results were also adjusted with Charlson’s comorbidity 
index and the subgroup analysis by stratifying Charlson’s comorbidity index found similar 
results. Secondly, lifestyle interventions such as regular exercise and diet modification which 
may contribute to CVD risk were not taken into account in the analysis. However, the disease 
characteristics such as duration of T2DM and the severity of chronic kidney disease and 
some key clinical parameters like BMI, waist circumference, HbA1c, BP, and lipid, to a 
certain extent, reflect the intensity of disease severity and lifestyle modification, have been 
considered. Thirdly, this study highlighted the relationship between low BP level and the 
increased risks of CVD and all-cause mortality. However, this pattern of association between 
BP and outcomes excluded cluster effect across clinics and thus may differ in the general 
population and other Chinese diabetic populations from other regions. The relationship may 
be subject to temporal changes and modifications in unmeasured risk factors or interventions. 
Researchers should be cautious when adopting the study findings in other settings. Lastly, the 
long-term effects on BP on CVD and all-cause mortality are uncertain among Chinese 
diabetic patients. Further longitudinal studies with longer follow-up period are warranted to 
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reappraise the association between low BP and incidence CVD events and mortality to 
confirm the reasons contributing to the excess mortality at lower BP. 
 
Perspectives 
This large territory wide naturalistic primary care study showed a J-shaped pattern between 
SBP and risks of all-cause mortality and CVD events including CHD, stroke and heart failure. 
The increased risk associated with low levels of SBP (< 125mmHg) should make clinicians 
cautious against overtreatment of Chinese hypertensive T2DM patients without existing 
complications. The level of achieved SBP of 125-139mmHg in pharmacological therapy, 
irrespective of gender, age, smoking status, duration of DM, BMI, kidney function, severity 
of comorbidities and treatment modalities, support the SBP treatment goal of < 140mmHg 
and the individualized SBP target may not be necessary in diabetic management. 
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Novelty and Significance 
What Is New? 
This first large territory wide naturalistic primary care study showed that the systolic blood 
pressure range for the lowest risk of cardiovascular diseases and all-cause mortality was 
130-134mmHg amongst Chinese patients with type 2 diabetes mellitus and hypertension 
managed in primary care. The current findings also demonstrated a J-shaped curvilinear 
relationship between systolic blood pressure and cardiovascular diseases incidence and 
all-cause mortality among diabetic population, irrespective of patients’ characteristics.  
 
What Is Relevant?  
Our findings contribute to improve the knowledge on the effect of systolic blood pressure on 
cardiovascular diseases and all-cause mortality for Chinese diabetic patients. 
 
Summary 
Lower blood pressure is not always better and may even be harmful, irrespective of patients’ 
characteristics, and thus the individualized systolic blood pressure target may not be 
necessary in diabetic management. 
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Figure Legends 
 
Figure 1. Adjusted hazard ratios for incidence of (A) cardiovascular diseases, (B) coronary 
heart disease, (C) stroke, (D) heart failure, (E) all-cause mortality and (F) composite of 
cardiovascular disease and mortality among all subjects by multivariable Cox proportional 
hazards regressions. Hazard ratios were adjusted by age, gender, smoking status, BMI, 
haemoglobin A1c, diastolic blood pressure, triglyceride, total cholesterol to high-density 
lipoprotein cholesterol ratio, low-density lipoprotein cholesterol, eGFR, duration of DM, the 
usages of ACEI/ARB, β-blocker, CCB, diuretic, other anti-hypertensive drugs, oral-diabetic 
drugs, insulin and lipid-lowering agent, and Charlson’s Index at baseline. 
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Tables 
Table 1. Baseline characteristics among subjects, stratified by systolic blood pressure 
Characteristic 
Total  
(N=95,08
6) 
SBP 
Group 1 
(<120mm
Hg) 
(N=3,314
) 
SBP 
Group 2 
(120-124
mmHg) 
(N=6,183
) 
SBP 
Group 3 
(125-129
mmHg) 
(N=12,14
0) 
SBP 
Group 4 
(130-134
mmHg) 
(N=17,76
5) 
SBP 
Group 5 
(135-139
mmHg) 
(N=19,27
1) 
SBP 
Group 6 
(140-144
mmHg) 
(N=15,68
3) 
SBP 
Group 7 
(145-149
mmHg) 
(N=9,893
) 
SBP 
Group 8 
(150-154
mmHg) 
(N=5,402
) 
SBP 
Group 9 
(155-159
mmHg) 
(N=2,698
) 
SBP 
Group 10 
(≥160mm
Hg) 
(N=2,737
) 
P-valu
e 
Socio-demographics 
            
Male 42.8% 43.5% 42.9% 43.5% 43.6% 43.6% 42.7% 41.6% 41.3% 39.6% 40.0% 
<0.00
1* 
Age, years 66.66±10. 65.97±11. 65.00±11. 64.75±10. 65.25±10. 66.24±10. 67.42±10. 68.68±10. 69.70±10. 70.18±11. 70.85±11. <0.00
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98 71 27 94 85 72 66 57 65 01 26 1* 
Current smoker 8.7% 11.0% 9.2% 9.1% 9.0% 8.7% 8.5% 8.2% 7.8% 8.0% 8.1% 
<0.00
1* 
             
Clinical parameters 
           
 
HbA1c, % 7.35±1.42 7.04±1.25 7.13±1.25 7.19±1.29 7.27±1.32 7.35±1.35 7.43±1.39 7.49±1.52 7.54±1.49 7.64±1.74 7.79±1.75 
<0.00
1* 
BMI, kg/m2 
25.83±6.0
2 
25.53±4.4
4 
25.69±4.4
3 
25.85±4.0
3 
25.97±5.3
4 
25.87±4.3
1 
25.86±4.7
2 
25.79±6.1
6 
25.72±4.8
8 
25.66±4.5
5 
25.59±5.6
8 
<0.00
1* 
Baseline SBP, mmHg 
141.49±1
7.59 
118.42±1
2.35 
126.26±1
3.42 
131.48±1
3.70 
136.95±1
4.03 
141.85±1
4.07 
146.38±1
4.26 
150.66±1
4.68 
155.19±1
4.97 
159.63±1
6.24 
169.12±1
8.92 
<0.00
1* 
Mean SBP, mmHg 137.62±1 115.82±3. 122.69±1. 127.63±1. 132.52±1. 137.38±1. 142.28±1. 147.16±1. 152.12±1. 157.08±1. 167.91±8. <0.00
 Page 34 of 45 
0.74 95 44 44 43 44 43 42 42 41 61 1* 
DBP, mmHg 
75.76±11.
04 
68.83±10.
13 
72.06±10.
35 
73.93±10.
55 
75.40±10.
69 
76.17±10.
68 
76.90±10.
82 
77.16±10.
95 
77.97±11.
33 
78.55±11.
70 
81.49±12.
78 
<0.00
1* 
LDL-C, mmol/L 3.16±1.29 3.13±1.03 3.14±0.95 3.15±1.03 3.15±0.93 3.15±1.01 3.16±0.96 3.17±1.03 3.20±1.14 3.20±1.05 3.24±1.03 
<0.00
1* 
TC/HDL-C ratio 4.52±1.81 4.48±1.50 4.51±1.66 4.53±1.59 4.51±1.40 4.51±1.85 4.51±1.84 4.52±1.57 4.55±1.87 4.59±1.52 4.62±2.08 
0.019
* 
Triglyceride, mmol/L 1.77±1.35 1.73±1.33 1.79±1.33 1.78±1.58 1.78±1.24 1.76±1.24 1.75±1.28 1.75±1.37 1.75±1.57 1.80±1.40 1.79±1.51 0.195 
eGFR < 
60ml/min/1.73m2 
18.2% 18.7% 16.7% 15.2% 15.6% 16.8% 18.8% 21.1% 23.7% 25.9% 30.6% 
<0.00
1* 
             Disease 
characteristics 
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Duration of DM, years 7.71±7.11 7.61±6.63 7.24±6.31 7.18±6.51 7.34±6.55 7.63±7.68 7.88±6.91 8.32±7.64 8.36±7.85 8.44±7.62 8.86±7.99 
<0.00
1* 
             Treatment modalities 
            
Charlson’s Index 4.10±1.07 4.04±1.17 3.95±1.13 3.93±1.10 3.97±1.08 4.06±1.06 4.17±1.04 4.28±1.02 4.36±1.01 4.38±1.00 4.44±1.05 
<0.00
1* 
Use of ACEI/ARB 46.6% 41.2% 41.8% 42.6% 45.3% 47.2% 48.3% 49.3% 50.4% 51.6% 53.7% 
<0.00
1* 
Use of β-blocker 37.4% 40.4% 38.5% 37.9% 36.7% 36.2% 36.8% 37.6% 38.2% 39.1% 40.8% 
<0.00
1* 
Use of CCB 54.1% 61.5% 57.7% 55.7% 53.3% 52.5% 51.8% 53.9% 55.8% 56.8% 55.0% 
<0.00
1* 
Use of Diuretic 15.9% 14.7% 14.4% 14.9% 15.0% 16.1% 16.9% 16.8% 17.0% 16.3% 16.4% <0.00
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1* 
Use of other 
anti-hypertensive 
drugs 
13.6% 12.8% 10.7% 11.6% 11.8% 13.4% 14.5% 15.7% 17.7% 18.1% 18.9% 
<0.00
1* 
Oral anti-diabetic drug 
used 
85.0% 81.9% 82.4% 82.8% 84.4% 85.1% 86.0% 86.9% 87.6% 87.7% 87.6% 
<0.00
1* 
Insulin used 0.8% 1.3% 0.5% 0.7% 0.7% 0.6% 0.8% 1.0% 1.3% 1.3% 1.5% 
<0.00
1* 
Lipid-lowering agents 
used 7.3% 7.2% 7.7% 7.6% 7.5% 7.2% 7.1% 6.6% 7.1% 7.6% 8.0% 
0.081 
HbA1c = Haemoglobin A1c; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; LDL-C = 
Low-density Lipoprotein-Cholesterol; TC = Total Cholesterol; HDL-C = High-density Lipoprotein-Cholesterol; ACR = Albumin/Creatinine 
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Ratio; eGFR = Estimated Glomerular Filtration Rate; DM = Diabetes Mellitus; ACEI = Angiotensin Converting Enzyme Inhibitor; ARB = 
Angiotensin Receptor Blocker; CCB = Calcium Channel Blocker 
 
Notes: 
All parameters are expressed in either percentage or mean ± sd. 
* Significant difference (P < 0.05) by ANOVA or chi-square test, as appropriate 
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Table 2. Number, incidence rate and hazard ratio of cardiovascular diseases events and all-cause mortality, stratified by systolic blood pressure 
Outcome 
SBP Group 
1 
(<120mmH
g) 
(N=3,314) 
SBP Group 
2 
(120-124m
mHg) 
(N=6,183) 
SBP Group 
3 
(125-129m
mHg) 
(N=12,140) 
SBP Group 
4 
(130-134m
mHg) 
(N=17,765) 
SBP Group 
5 
(135-139m
mHg) 
(N=19,271) 
SBP Group 
6 
(140-144m
mHg) 
(N=15,683) 
SBP Group 
7 
(145-149m
mHg) 
(N=9,893) 
SBP Group 
8 
(150-154m
mHg) 
(N=5,402) 
SBP Group 
9 
(155-159m
mHg) 
(N=2,698) 
SBP Group 
10 
(≥160mmHg) 
(N=2,737) 
CVD 
          
Cumulative cases 
with event 
727 925 1,455 2,144 2,491 2,495 2,068 1,454 863 1,199 
Cumulative 
Incidence Rate 
21.9% 15.0% 12.0% 12.1% 12.9% 15.9% 20.9% 26.9% 32.0% 43.8% 
Person-years 17,558 36,715 74,471 109,494 118,567 94,348 56,992 29,220 13,567 11,363 
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Median 
follow-up (Months) 80.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 75.5 51.5 
Incidence rate 
(95% CI)† 
41.40 
(38.50,44.5
3) 
25.19 
(23.62,26.87
) 
19.54 
(18.56,20.57
) 
19.58 
(18.77,20.4
3) 
21.01 
(20.20,21.85
) 
26.44 
(25.43,27.50
) 
36.29 
(34.76,37.8
8) 
49.76 
(47.27,52.39
) 
63.61 
(59.51,68.00
) 
105.52 
(99.71,111.66
) 
Hazard ratio‡ 
(95% CI) 
2.06* 
(1.89,2.24) 
1.31* 
(1.21,1.41) 
1.02 
(0.96,1.10) 
Reference 
group 
1.02 
(0.97,1.08) 
1.22* 
(1.15,1.29) 
1.56* 
(1.47,1.66) 
2.05* 
(1.92,2.19) 
2.54* 
(2.35,2.76) 
4.15* 
(3.86,4.47) 
CHD 
          
Cumulative cases 
with event 
356 455 728 1,044 1,163 1,152 950 655 408 559 
Cumulative 
Incidence Rate 
10.7% 7.4% 6.0% 5.9% 6.0% 7.3% 9.6% 12.1% 15.1% 20.4% 
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Person-years 18,842 38,000 76,450 112,364 121,804 97,906 60,257 31,730 15,055 13,715 
Median 
follow-up (Months) 81.5 81.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 74.5 
Incidence rate 
(95% CI)† 
18.89 
(17.03,20.9
6) 
11.97 
(10.92,13.13
) 
9.52 
(8.86,10.24) 
9.29 
(8.74,9.87) 
9.55 
(9.01,10.11) 
11.77 
(11.11,12.47
) 
15.77 
(14.79,16.8
0) 
20.64 
(19.12,22.29
) 
27.10 
(24.59,29.86
) 
40.76 
(37.52,44.28) 
Hazard ratio‡ 
(95% CI) 
1.89* 
(1.68,2.14) 
1.28* 
(1.15,1.43) 
1.04 
(0.95,1.14) 
Reference 
group 
0.99 
(0.91,1.08) 
1.17* 
(1.08,1.28) 
1.48* 
(1.36,1.62) 
1.87* 
(1.69,2.06) 
2.38* 
(2.12,2.67) 
3.52* 
(3.16,3.91) 
Stroke 
          
Cumulative cases 
with event 
311 364 615 917 1,067 1,064 867 606 348 519 
Cumulative 9.4% 5.9% 5.1% 5.2% 5.5% 6.8% 8.8% 11.2% 12.9% 19.0% 
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Incidence Rate 
Person-years 18,828 38,184 76,529 112,286 121,905 97,792 60,116 31,379 15,035 13,305 
Median 
follow-up (Months) 81.5 81.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 72.5 
Incidence rate 
(95% CI)† 
16.52 
(14.78,18.4
6) 
9.53 
(8.60,10.56) 
8.04 
(7.43,8.70) 
8.17 
(7.65,8.71) 
8.75 
(8.24,9.29) 
10.88 
(10.25,11.55
) 
14.42 
(13.49,15.4
1) 
19.31 
(17.83,20.91
) 
23.15 
(20.84,25.71
) 
39.01 
(35.79,42.51) 
Hazard ratio‡ 
(95% CI) 
1.96* 
(1.72,2.23) 
1.18* 
(1.04,1.33) 
1.01 
(0.91,1.12) 
Reference 
group 
1.02 
(0.93,1.11) 
1.20* 
(1.10,1.31) 
1.47* 
(1.34,1.62) 
1.87* 
(1.69,2.08) 
2.16* 
(1.91,2.45) 
3.53* 
(3.16,3.94) 
Heart Failure 
          
Cumulative cases 
with event 
197 262 386 572 733 790 727 534 332 463 
 Page 42 of 45 
Cumulative 
Incidence Rate 
5.9% 4.2% 3.2% 3.2% 3.8% 5.0% 7.3% 9.9% 12.3% 16.9% 
Person-years 19,367 38,615 77,349 113,522 123,154 98,924 61,017 32,000 15,322 14,059 
Median 
follow-up (Months) 81.5 81.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 77.5 
Incidence rate 
(95% CI)† 
10.17 
(8.85,11.70) 
6.78 
(6.01,7.66) 
4.99 
(4.52,5.51) 
5.04 
(4.64,5.47) 
5.95 
(5.54,6.40) 
7.99 
(7.45,8.56) 
11.91 
(11.08,12.8
1) 
16.69 
(15.33,18.16
) 
21.67 
(19.46,24.13
) 
32.93 
(30.06,36.07) 
Hazard ratio‡ 
(95% CI) 
1.76* 
(1.50,2.07) 
1.33* 
(1.15,1.55) 
1.02 
(0.89,1.16) 
Reference 
group 
1.10 
(0.99,1.23) 
1.37* 
(1.23,1.53) 
1.82* 
(1.63,2.03) 
2.36* 
(2.09,2.66) 
2.96* 
(2.58,3.40) 
4.34* 
(3.82,4.93) 
All-cause Mortality           
Cumulative cases 665 712 1,113 1,537 1,727 1,707 1,304 920 584 765 
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with event 
Cumulative 
Incidence Rate 
20.1% 11.5% 9.2% 8.7% 9.0% 10.9% 13.2% 17.0% 21.6% 28.0% 
Person-years 19,883 39,193 78,176 114,635 124,538 100,552 62,610 33,224 16,118 15,191 
Median 
follow-up (Months) 81.5 81.5 81.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 
Incidence rate 
(95% CI)† 
33.45 
(31.00,36.0
9) 
18.17 
(16.88,19.55
) 
14.24 
(13.42,15.10
) 
13.41 
(12.75,14.1
0) 
13.87 
(13.23,14.54
) 
16.98 
(16.19,17.80
) 
20.83 
(19.73,21.9
9) 
27.69 
(25.96,29.54
) 
36.23 
(33.41,39.29
) 
50.36 
(46.91,54.06) 
Hazard ratio‡ 
(95% CI) 
2.26* 
(2.06,2.48) 
1.35* 
(1.23,1.47) 
1.09* 
(1.01,1.18) 
Reference 
group 
0.96 
(0.89,1.03) 
1.09* 
(1.02,1.17) 
1.20* 
(1.11,1.29) 
1.48* 
(1.36,1.61) 
1.86* 
(1.69,2.05) 
2.50* 
(2.29,2.74) 
Composite of CVD           
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and Mortality 
Cumulative cases 
with event 
1,133 1,360 2,159 3,120 3,549 3,495 2,751 1,912 1,147 1,518 
Cumulative 
Incidence Rate 
34.2% 22.0% 17.8% 17.6% 18.4% 22.3% 27.8% 35.4% 42.5% 55.5% 
Person-years 17,558 36,715 74,471 109,494 118,567 94,348 56,992 29,220 13,567 11,363 
Median 
follow-up (Months) 80.5 81.5 81.5 81.5 81.5 81.5 81.5 80.5 75.5 51.5 
Incidence rate 
(95% CI)† 
64.53 
(60.88,68.4
0) 
37.04 
(35.12,39.06
) 
28.99 
(27.79,30.24
) 
28.49 
(27.51,29.5
1) 
29.93 
(28.96,30.93
) 
37.04 
(35.84,38.29
) 
48.27 
(46.50,50.1
1) 
65.43 
(62.57,68.43
) 
84.55 
(79.79,89.58
) 
133.59 
(127.04,140.4
8) 
Hazard ratio‡ 2.23* 1.33* 1.05 Reference 0.99 1.16* 1.41* 1.83* 2.30* 3.61* 
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(95% CI) (2.08,2.38) (1.24,1.41) (0.99,1.11) group (0.95,1.04) (1.11,1.22) (1.34,1.48) (1.73,1.94) (2.15,2.47) (3.39,3.85) 
SBP = Systolic Blood Pressure; CVD = Cardiovascular Disease; CHD = Coronary Heart Disease; CI = Confidence Interval 
 
Notes: 
* Significant difference (P < 0.05) by multivariable Cox proportional hazards regression 
† Incidence rate (cases/1000 person-years) with 95%CI based on Poisson Distribution 
‡ Hazard ratios were adjusted age, gender, smoking status, body mass index, haemoglobin A1c, diastolic blood pressure, triglyceride, total cholesterol 
to high-density lipoprotein cholesterol ratio, low-density lipoprotein cholesterol, estimated glomerular filtration rate, duration of diabetes mellitus, the 
usages of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other anti-hypertensive 
drugs, oral-diabetic drugs, insulin and lipid-lowering agent, and Charlson’s Index at baseline. 
